ZOMETA® | Dosing For Tumour-Induced Hypercalcaemia (TIH): Ensuring Renal Safety

View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics

Zometa Dosing & Administration: Dosing for TIH

ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

Assess renal function prior to treatment in patients with TIH

The risks and benefits of therapy should be evaluated in patients with TIH who have severe renal impairment¹
No dose adjustment is necessary in patients with serum creatinine <400 μmol/L or <4.5 mg/dL¹
- — Patients with higher serum creatinine levels were not included in clinical studies of ZOMETA^® in TIH

Disclaimer: This is an international website for ZOMETA^® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.